2-氯-5-甲基噻吩 | 17249-82-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-氯-5-甲基噻吩
• 中文别名: 2-氯-5-甲基硫代苯
• 英文名称: 2-chloro-5-methylthiophene
• 英文别名: 5-chloro-2-methylthiophene；5-methyl-2-chlorothiophene；2-methyl-5-chlorothiophene
• CAS: 17249-82-0
• 化学式: C₅H₅ClS
• mdl: MFCD01632145
• 分子量: 132.614
• InChiKey: JSMMZMYGEVUURX-UHFFFAOYSA-N

物化性质

• 沸点：
  155-156°C
• 密度：
  1.21
• 闪点：
  155-156°C
• 稳定性/保质期：
  常温常压下稳定，应避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  3
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2934999090
• 危险品运输编号：
  UN 1993 3/PG III
• 包装等级：
  III
• 危险类别：
  3
• 危险性防范说明：
  P210,P233,P240,P241+P242+P243,P264,P280,P302+P352+P332+P313+P362+P364,P305+P351+P338+P337+P313,P403+P235,P501
• 危险性描述：
  H225,H315,H319
• 储存条件：
  常温下应密闭避光保存，并置于通风干燥处。

SDS

---

Section I.Chemical Product and Company Identification
Chemical Name 2-Chloro-5-methylthiophene
Portland OR
Synonym Thiophene, 2-chloro-5-methyl- (CA INDEX NAME)
Chemical Formula C5H5ClS
CAS Number 17249-82-0

---

Section II. Composition and Information on Ingredients
Toxicology Data
Chemical Name CAS Number Percent (%) TLV/PEL
2-Chloro-5-methylthiophene 17249-82-0 Min. 96.0 (GC) Not available. Not available.

---

Section III. Hazards Identification
Acute Health Effects Harmful if ingested or inhaled. Minimize exposure to this material. Severe overexposure can result in injury or death.
Irritating to eyes and skin on contact. Inhalation causes irritation of the lungs and respiratory system. Inflammation of the
eye is characterized by redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening, or,
occasionally, blistering.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
Chronic Health Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.

---

Section IV. First Aid Measures
Eye Contact Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Get medical attention.
Skin Contact In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing
before reuse. Thoroughly clean shoes before reuse. Get medical attention.
If the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
Inhalation
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Ingestion
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the toxic
material was ingested; the absence of such signs, however, is not conclusive.

---

Section V. Fire and Explosion Data
Not available.
Combustible. Auto-Ignition
Flammability
Flash Points Flammable Limits Not available.
47°C (116.6°F).
These products are toxic carbon oxides (CO, CO2), halogenated compounds, sulfur oxides (SOx).
Combustion Products
WARNING: Highly toxic HCl gas is produced during combustion.
Fire Hazards
Not available.
Risks of explosion of the product in presence of mechanical impact: Not available.
Explosion Hazards
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media
Flammable liquid.
SMALL FIRE: Use DRY chemical powder.
and Instructions
LARGE FIRE: Use alcohol foam, water spray or fog. Cool containing vessels with water jet in order to prevent pressure
build-up, autoignition or explosion. Consult with local fire authorities before attempting large scale fire-fighting operations.
Continued on Next Page
2-Chloro-5-methylthiophene

---

Section VI. Accidental Release Measures
Spill Cleanup Combustible material. Harmful material. Irritating material.
Keep away from heat. Mechanical exhaust required. Stop leak if without risk. Absorb with DRY earth, sand or other
Instructions
non-combustible material. DO NOT touch spilled material. Prevent entry into sewers, basements or confined areas; dike if
needed. Consult federal, state, and/or local authorities for assistance on disposal.

---

Section VII. Handling and Storage
COMBUSTIBLE. HARMFUL. IRRITANT. Keep away from heat. Mechanical exhaust required. Avoid excessive heat and
Handling and Storage
light. Do not breathe gas/fumes/ vapor/spray.
Information
Always store away from incompatible compounds such as oxidizing agents.

---

Section VIII. Exposure Controls/Personal Protection
Provide exhaust ventilation or other engineering controls to keep the airborne concentrations of vapors below their respective
Engineering Controls
threshold limit value. Ensure that eyewash station and safety shower is proximal to the work-station location.
Splash goggles. Lab coat. Vapor respirator. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a
Personal Protection
specialist BEFORE handling this product. Be sure to use a MSHA/NIOSH approved respirator or equivalent.
Exposure Limits Not available.

---

Section IX. Physical and Chemical Properties
Liquid. (Clear, light yellow.) Solubility
Physical state @ 20°C Immiscible with water.
1.21 (water=1)
Specific Gravity
Molecular Weight 132.61 Partition Coefficient
Not available.
Boiling Point 155°C (311°F) Vapor Pressure Not available.
Not available. Not available.
Melting Point Vapor Density
Refractive Index 1.54 Volatility Not available.
Not available. Not available.
Critical Temperature Odor
Viscosity Not available. Taste Not available.

---

Section X. Stability and Reactivity Data

---

This material is stable if stored under proper conditions. (See Section VII for instructions)
Stability
Conditions of Instability Avoid excessive heat and light.
Incompatibilities
Reactive with oxidizing agents.

---

Section XI. Toxicological Information
Not available.
RTECS Number
Eye Contact. Ingestion. Inhalation.
Routes of Exposure
Not available.
Toxicity Data
Chronic Toxic Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
Harmful if ingested or inhaled. Minimize exposure to this material. Severe overexposure can result in injury or death.
Acute Toxic Effects
Irritating to eyes and skin on contact. Inhalation causes irritation of the lungs and respiratory system. Inflammation of the eye
is characterized by redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening, or,
occasionally, blistering.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.

---

Section XII. Ecological Information
Not available.
Ecotoxicity
Environmental Fate Not available.
Continued on Next Page
2-Chloro-5-methylthiophene

---

Section XIII. Disposal Considerations
Waste Disposal Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.

---

Section XIV. Transport Information
DOT Classification DOT CLASS 3: Flammable liquid.
PIN Number
Proper Shipping Name Flammable liquid, n.o.s.
Packing Group (PG) III
DOT Pictograms

---

Section XV. Other Regulatory Information and Pictograms
TSCA Chemical Inventory This product is NOT on the EPA Toxic Substances Control Act (TSCA) inventory. The following notices are required by 40
CFR 720.36 (C) for those products not on the inventory list:
(EPA)
(i) These products are supplied solely for use in research and development by or under the supervision of a technically
qualified individual as defined in 40 CFR 720.0 et sec.
(ii) The health risks of these products have not been fully determined. Any information that is or becomes available will be
supplied on an MSDS sheet.
WHMIS Classification CLASS B-3: Combustible liquid with a flash point between 37.8°C (100°F) and 93.3°C (200°F).
(Canada)
EINECS Number (EEC) Not available.
EEC Risk Statements R10- Flammable.
R18- In use, may form flammable/explosive vapor-air mixture.
R20/21/22- Harmful by inhalation, in contact with skin and if swallowed.
R36/37/38- Irritating to eyes, respiratory system and skin.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-5-甲基噻吩 在 palladium 10% on activated carbon 、 氢气 、 potassium hydroxide 作用下， 80.0 ℃ 、8.0 MPa 条件下， 反应 24.0h， 以97.11%的产率得到2-甲基噻吩
  参考文献：
  名称：

  一种分离包含甲苯、2-甲基噻吩和3-甲基噻吩 的混合物中各组分的方法

  摘要：

  本发明属于化工技术领域，具体涉及一种分离包含甲苯、2‑甲基噻吩和3‑甲基噻吩的混合物中各组分的方法。本发明首次采用化学法将沸点很接近的含有甲苯、2‑甲基噻吩、3‑甲基噻吩的混合物中2‑甲基噻吩和3‑甲基噻吩转变成沸点与甲苯相差较大的物质2‑氯‑5‑甲基噻吩和2,5‑二氯‑3‑甲基噻吩，然后采用精馏的方法将各组分进行分离和提纯，2‑氯‑5‑甲基噻吩和2,5‑二氯‑3‑甲基噻吩经还原等方法处理得到单一组分的2‑甲基噻吩和3‑甲基噻吩，使三者分离。本发明的方法工艺简单，产品收率和纯度高、分离效果好、能耗低，没有三废排放，是一种绿色分离工艺。

  公开号：

  CN110498763B
• 作为产物：
  描述：

  2-甲基噻吩 在 三甲基氯硅烷 、 [双(三氟乙酰氧基)碘]苯 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以86%的产率得到2-氯-5-甲基噻吩
  参考文献：
  名称：

  原位生成超价碘试剂用于芳烃的亲电氯化反应

  摘要：

  据报道，使用PIFA和简单的氯源进行芳烃的亲电氯化的高效无金属方法。当分别使用PIFA–KCl和PIFA–TMSCl的组合时，有人建议原位形成不同的基于I（III）的物质，例如PhI（OCOCF 3）Cl和PhICl 2作为氯化剂。

  DOI：

  10.1002/ejoc.201900237

文献信息

• [EN] METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS<br/>[FR] PROCEDES DE TRAITEMENT D'AMYLOIDOSE UTILISANT DES INHIBITEURS DE PROTEASE ASPARTYLE
  申请人：ELAN PHARM INC

  公开号：WO2005070407A1

  公开（公告）日：2005-08-04

  The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及乙酰2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗与淀粉样变性相关的疾病、疾病和症状。淀粉样变性是指与A-beta蛋白异常沉积相关的一系列疾病、疾病和症状。
• Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20060014737A1

  公开（公告）日：2006-01-19

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及新型化合物和治疗与淀粉样变性相关的疾病、紊乱和症状的方法。淀粉样变性指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和症状。
• POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：DE PERETTI Danielle

  公开号：US20110065727A1

  公开（公告）日：2011-03-17

  Compounds of formula (I): wherein R, R 1 , R 2 , R 3 , R 4 and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

  式（I）的化合物： 其中R、R1、R2、R3、R4和X如披露中所定义，或其酸盐，以及其治疗用途和合成过程。
• [EN] METHODS AND COMPOSITIONS FOR INHIBITION OF RAS<br/>[FR] MÉTHODES ET COMPOSITIONS PERMETTANT L'INHIBITION DE LA RAS
  申请人：ARAXES PHARMA LLC

  公开号：WO2016049568A1

  公开（公告）日：2016-03-31

  Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer.

  提供了Ras蛋白的抑制剂，调节Ras蛋白活性的方法，以及通过Ras蛋白介导的疾病治疗方法。描述了一种使用化合物调节K-Ras、H-Ras或N-Ras突变蛋白活性的方法。可治疗的疾病包括癌症，如血液癌症、胰腺癌、MYH相关性息肉症、结直肠癌或肺癌。
• [EN] INHIBITORS OF KRAS G12C<br/>[FR] INHIBITEURS DE K-RAS G12C
  申请人：ARAXES PHARMA LLC

  公开号：WO2015054572A1

  公开（公告）日：2015-04-16

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）：或其药用可接受的盐、互变异构体、前药或立体异构体，其中R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z和E如本文所定义。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。